Unidad de Atencion Medica e Investigacion en Salud (UNAMIS) | Clinical Protocols Department

Research site

Location

Calle 33-A No. 505 entre 72 y 72-A Colonia Centro, Merida, Yucatán, Mexico

Site insights

Top conditions

Top treatments

Risankizumab

Ontamalimab

Dazodalibep

HZN-825

Avastin

Doravirine

Pregabalin

Afimetoran

CC-220

Celecoxib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Juan José Rivera Alcocer

Verified by this site

Active trials

6 of 23 total trials

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Primary Objective:To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom stateSecon...

Enrolling

Sjögren's Syndrome (SS)

Drug: Dazodalibep

Drug: Placebo

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythema...

Enrolling

Systemic Lupus Erythematosus

Other: Placebo

Drug: Afimetoran

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease (FORTIFY)

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting

Crohn's Disease

Drug: Placebo for Risankizumab IV

Drug: Risankizumab SC

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis (COMMAND)

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting

Ulcerative Colitis (UC)

Drug: placebo for risankizumab

Drug: risankizumab

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Primary Objective:To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe...

Enrolling

Sjogren's Syndrome

Drug: Dazodalibep

Drug: Placebo

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)

This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 wee...

Enrolling

Human Immunodeficiency Virus (HIV) Infection

Drug: 2 NRTIs

Drug: Doravirine